Collectively, our findings reveal a novel phosphorylation site on the NLRP3 protein that positively regulates inflammasome activation and introduce an effective NLRP3 inhibitor with potential for PD therapy and other NLRP3 inflammasome-driven diseases. Here, NLRP3 is linked to Parkinson disease.